|
|
|
(Journal Article): NN-2211 Novo Nordisk.
Mark M (Boehringer Ingelheim Pharma GmbH & Co KG, Department of Metabolic Research, Birkendorfer Strasse 65 88397, Biberach an der Riss, Germany.,
michael.mark@bc.boehringer-ingelheim.com
)
IN:
IDrugs
2003; 6(3):251-258
Fulltext:
PDF
ABSTRACT: Novo Nordisk A/S, under license from Scios Inc, is developing NN-2211, a stable analog of the naturally occurring peptide hormone glucagon-like peptide 1 (GLP-1), which stimulates insulin release in response to increases in blood sugar levels, for the potential treatment of type 2 diabetes.
TYPE OF PUBLICATION: Original article
Articles citing this article:
|
Respond
on this Journal Article!
Hint: Your Response should directly apply to NN-2211 Novo Nordisk..
Please check, if this context applies best to your contribution. Otherwise click HERE to change to the appropriate
subject area. The actual subject area is Incretin Mimetics.
|
|
|
|
|
